A Look At Masimo (MASI) Valuation After Recent Share Price Rebound

Context for Masimo after recent share price moves

Masimo (MASI) has been drawing investor attention after a strong month in the share price, with the stock closing at $175.97 and recent returns prompting closer scrutiny of its fundamentals.

See our latest analysis for Masimo.

Beyond the recent surge, Masimo’s share price return of 35.21% over the past 30 days and 29.66% over 90 days contrasts with a far more modest 4.64% one year total shareholder return. This suggests momentum has picked up only recently while longer term holders have seen limited gains.

If this kind of rebound has you thinking about what else could be setting up for a move, it may be worth scanning for other healthcare names using our focused screener for emerging medical technology, starting with 35 healthcare AI stocks.

With Masimo now trading close to its US$178.60 analyst price target after a sharp rebound, the key question is whether the current valuation still leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 1.5% Undervalued

Masimo's latest fair value estimate of $178.60 sits just above the last close at $175.97, so the current debate is about a very small valuation gap rather than a large mispricing.

The revenue growth input shifts from a 5.81% decline to a 6.62% increase, reflecting a move from contraction to modest growth in the forward assumptions for $ revenue.

Net Profit Margin: The net profit margin estimate is trimmed slightly from 16.43% to 16.32%, a very small change in expected profitability levels.

Read the complete narrative.

Curious what sits behind that small discount to fair value, and why higher growth, firm margins and a lower future P/E still support this price target?

Result: Fair Value of $178.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, if tariffs pressure manufacturing costs or hospital contract wins slow, the current growth and margin story supporting that fair value could quickly be questioned.

Find out about the key risks to this Masimo narrative.

Another angle on Masimo’s valuation

The fair value work above points to a small discount, but the current P/E of 44.2x tells a tougher story. It sits well above both the US Medical Equipment industry at 28.1x and Masimo’s own fair ratio of 24.6x, which points to clear valuation risk if expectations cool.

For context, that gap means you are paying a higher price than the wider industry and what the fair ratio suggests the market could move toward, while still relying on earnings forecasts that are slower than the broader US market. Is that premium level of optimism something you are comfortable with?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed in the discussion above, it makes sense to review the facts for yourself and then weigh both sides of the story. To help frame that view, take a closer look at the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at one company, you risk missing opportunities that better match your goals, so take a few minutes to compare other ideas side by side.

• Target quality at a discount by reviewing 48 high quality undervalued stocks, which combine solid fundamentals with pricing that may appeal to value focused investors.
• Prioritise resilience by checking 76 resilient stocks with low risk scores, which score well on stability for investors who care about smoother portfolio swings.
• Hunt for tomorrow's leaders before the crowd sees them by scanning screener containing 27 high quality undiscovered gems, which stand out on fundamentals but still fly under most radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com